RecruitingPhase 2NCT04644016

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

31 participants

Start Date

Nov 20, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.


Eligibility

Max Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This study is offering cord blood transplants — a type of stem cell transplant using blood collected from umbilical cords after birth — to children and young adults with blood cancers or non-cancerous blood disorders who do not have a matched donor available. Cord blood transplants can expand access to life-saving transplants for patients without a suitable bone marrow match. **You may be eligible if...** - You are 21 years old or younger - You do not have a suitable matched related or unrelated bone marrow donor available in time - You have been diagnosed with leukemia (AML or ALL) in remission or relapse, myelodysplastic syndrome, lymphoma, sickle cell disease, thalassemia, or another serious blood disorder - Specific disease and remission status requirements vary — your transplant team will assess eligibility **You may NOT be eligible if...** - You have a suitable matched related or unrelated donor available - Your disease is too advanced or uncontrolled to safely proceed to transplant - You have significant organ function problems that make transplant too dangerous Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGClofarabine

Clofarabine

DRUGFludarabine

Fludarabine

DRUGBusulfan

Busulfan per PK

DRUGCyclosporine-A

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

DRUGMycophenolate Mofetil

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

BIOLOGICALCord Blood Graft

The CB graft will be infused on day 0 per standard practice


Locations(1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04644016


Related Trials